Theravance Biopharma, Inc. Increase (Decrease) in Deferred Revenue
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Deferred Revenue of $17.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-02-28
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$3.00K.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was $5.00K.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$2.00K.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-03-31 was $17.00K, a 98.51% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for fiscal 2017 was $17.00K, a 96.21% decline from fiscal 2016.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $448.00K, a 51.86% increase from fiscal 2015.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for fiscal 2015 was $295.00K.
- Theravance Biopharma, Inc. increase (decrease) in deferred revenue for fiscal 2014 was -$7.99M, a 207.02% decline from fiscal 2013.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $2.00K derived: sum of 2 quarters · filed 2018-02-28 | $0.00 derived: sum of 3 quarters · filed 2018-02-28 | $17.00K 10-K · filed 2018-02-28 |
| 2017-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.00K derived: sum of 2 quarters · filed 2017-11-08 | $20.00K 10-Q · filed 2017-11-08 | -$14.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $15.00K 10-Q · filed 2017-08-09 | -$19.00K derived: sum of 3 quarters · filed 2018-02-28 | -$442.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2017-03-31 | $17.00K 10-Q · filed 2017-05-10 | -$17.00K derived: sum of 2 quarters · filed 2018-02-28 | -$440.00K derived: sum of 3 quarters · filed 2018-02-28 | -$676.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$457.00K derived: sum of 2 quarters · filed 2018-02-28 | -$693.00K derived: sum of 3 quarters · filed 2018-02-28 | $448.00K 10-K · filed 2018-02-28 |
| 2016-09-30 | -$423.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$659.00K derived: sum of 2 quarters · filed 2017-11-08 | $482.00K 10-Q · filed 2017-11-08 | $555.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | -$236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $905.00K 10-Q · filed 2017-08-09 | $978.00K derived: sum of 3 quarters · filed 2018-02-28 | $815.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $1.14M 10-Q · filed 2017-05-10 | $1.21M derived: sum of 2 quarters · filed 2018-02-28 | $1.05M derived: sum of 3 quarters · filed 2018-02-28 | $1.22M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $73.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | -$90.00K derived: sum of 2 quarters · filed 2018-02-28 | $83.00K derived: sum of 3 quarters · filed 2018-02-28 | $295.00K 10-K · filed 2018-02-28 |
| 2015-09-30 | -$163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $10.00K derived: sum of 2 quarters · filed 2016-11-09 | $222.00K 10-Q · filed 2016-11-09 | -$661.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $173.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $385.00K 10-Q · filed 2016-08-09 | -$498.00K derived: sum of 3 quarters · filed 2017-03-01 | -$5.27M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $212.00K 10-Q · filed 2016-05-10 | -$671.00K derived: sum of 2 quarters · filed 2017-03-01 | -$5.44M derived: sum of 3 quarters · filed 2017-03-01 | -$7.37M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$883.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$5.65M derived: sum of 2 quarters · filed 2017-03-01 | -$7.58M derived: sum of 3 quarters · filed 2017-03-01 | -$7.99M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$4.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$6.70M derived: sum of 2 quarters · filed 2015-11-12 | -$7.11M 10-Q · filed 2015-11-12 | -$6.84M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | -$1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$2.34M 10-Q · filed 2015-08-13 | -$2.08M derived: sum of 3 quarters · filed 2016-03-11 | -$1.64M derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | -$412.00K 10-Q · filed 2015-05-13 | -$147.00K derived: sum of 2 quarters · filed 2016-03-11 | $291.00K derived: sum of 3 quarters · filed 2016-03-11 | $787.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | $265.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $703.00K derived: sum of 2 quarters · filed 2016-03-11 | $1.20M derived: sum of 3 quarters · filed 2016-03-11 | $7.47M 10-K · filed 2016-03-11 |
| 2013-09-30 | $438.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $934.00K derived: sum of 2 quarters · filed 2014-11-12 | $7.20M 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $496.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $6.76M 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $6.27M 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | -$124.49M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |